Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
Public ClinicalTrials.gov record NCT00819091. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 18 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control (HbA1c 7.0-10%) Despite Background Therapy With a Sulfonylurea Drug.
Study identification
- NCT ID
- NCT00819091
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 245 participants
Conditions and interventions
Conditions
Interventions
- BI 1356 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2008
- Primary completion
- Dec 31, 2009
- Completion
- Not listed
- Last update posted
- Jun 26, 2014
Started 2008
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1218.35.10002 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1218.35.10001 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1218.35.10016 Boehringer Ingelheim Investigational Site | National City | California | — | — |
| 1218.35.10017 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1218.35.10021 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1218.35.10013 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1218.35.10015 Boehringer Ingelheim Investigational Site | Flint | Michigan | — | — |
| 1218.35.10018 Boehringer Ingelheim Investigational Site | Asheville | North Carolina | — | — |
| 1218.35.10004 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1218.35.10005 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1218.35.10020 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1218.35.10009 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1218.35.10019 Boehringer Ingelheim Investigational Site | Sugar Land | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00819091, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2014 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00819091 live on ClinicalTrials.gov.